Portfolio Companies | Former Portfolio Companies

“ExSAR Corporation is a development stage company dedicated to identifying, developing and commercializing small molecule therapeutics for protein misfolding diseases. ExSAR utilizes its Hydrogen/Deuterium exchange platform technology (H/D-Ex) to screen lead compounds for the ability to prevent protein misfolding and restore protein function. ExSAR provides H/D-Ex technology services to third parties to characterize proteins, including biogenerics and to identify ligand binding sites, typically in conjunction with fragment based drug discovery programs.” (www.exsar.com)

Pharmos acquired Vela and their drug for IBS-d (Irritable Bowel Syndrome). This drug is in a Phase II trial. (www.pharmoscorp.com)

Immunicon has developed and utilizes a magnetic separations technology for rare cell detection. The initial market for this technology is early detection of circulating cancer cells in blood. Immunicon has been aquired by J & J. (www.immunicon.com)

PharmaStem (formerly Biocyte) is focused on sourcing stem cells from umbilical cord blood as an an important alternative to cells from bone marrow and peripheral blood for treatment of cancers, immune-specific diseases and gene therapy.

Targent Inc. focuses on the repositioning and reformulation of older cancer therapeutics and is screening a range of new compounds for novel hits. Targent was sold to Spectrum Pharmaceuticals in 2006. (www.spectrumpharm.com)

i-STAT: (STAT) Develops and manufactures pocket-sized clinical chemistry analyzers and disposables providing accurate, real-time measurements of blood analytes for point-of-care testing. IStat was sold to Abbott Laboratories. (www.i-stat.com)